Clinical Trial Update: Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating eribulin with or without a trastuzumab biosimilar in patients with HER2-overexpressing recurrent or stage IV breast cancer, currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• Trastuzumab biosimilar

Snippet

Sponsor: Seoul National University Hospital | Conditions: Advanced Breast Cancer | Phase 2 | Status: RECRUITING